The Th17 lineage, a lineage of effector CD4 + T cells, is characterized by the production of IL-17. Expansion of Th17 cells has been implicated in a growing list of autoimmune disorders. Our studies, as well as others, have shown that Th17 cells play a key role in the pathogenesis of SLE. Therefore, some investigators advocate that Th17 cells are a promising therapeutic target for SLE. However, neutralization of IL-17 in vivo actually aggravated inflammation by inducing infiltration of other effector cells. Thus, the therapeutic effects of antagonizing Th17 cells for the treatment of SLE in the clinic are worth discussing. Moreover, in patients with SLE, the expansion of effector T cells is always closely related to the depletion and dysfunction of Treg cells. Therefore, we hypothesize that for the treatment of SLE, we should focus on therapeutic agents that can regulate the immune balance between Th17 and Treg cells rather than on those that exclusively regulate Th17 cells.
Introduction
A fine balance between effector T cells and Treg cells regulates immune homeostasis. However, in autoimmune diseases, the levels and functions of these cells are often disrupted. Th17 cells, a subset of effector CD4 + T cells, are identified based on their ability to produce IL-17A, IL-17F and IL-22 [1, 2] . These cells have become the focus of many immunity studies, with hundreds of studies characterizing their roles in promoting inflammation and autoimmunity [36] . Treg cells, in contrast, are capable of modulating the function of effector T cells, maintaining immunological homeostasis, and preventing autoimmunity [7, 8] . Although the immunological mechanism of SLE remains unclear, accumulating studies confirm that the expansion of Th17 cells and the dysfunction or depletion of Treg cells are closely related to the pathogenesis of SLE [6, 916] .
Evidence that Th17 cells play a role in SLE Previous studies have confirmed that IL-17 concentrations are elevated in patients with SLE [1619] . Meanwhile, IL-17 acts in synergy with B-cell-activating factor (BAFF) to promote B-cell differentiation and autoantibody production [20, 21] Regulation of Th17-cell differentiation by transcription factor
It was previously demonstrated that neither Th1-cell-nor Th2-cell-associated transcription factors are required for Th17-cell differentiation [50] . However, great progress has been made in identifying positive and negative regulatory transcriptional factors required for the differentiation of Th17 cells (Table 1) . Retinoic acid-receptor-related orphan receptor-gt (RORgt), signal transduction and activator of transcription 3 (STAT3), aryl hydrocarbon receptor (AHR), INF regulatory factor 4 (IRF4), B-cell-activating transcription factor (BATF), epidermal fatty acid-binding protein (E-FABP) and src-homology 2-containing inositol 5 0 phosphatase (SHIP) can positively mediate Th17 lineage commitment [5159] .
IL-6 and TGF-b together induce RORgt expression and Th17-cell differentiation [53] . At low concentrations, TGF-b synergizes with IL-6 to promote Th17-cell differentiation. However, high concentrations of TGF-b favour forkhead box p3 (Foxp3 + ) Treg cells and up-regulation of Foxp3 might further inhibit RORgt activity [39] (Fig. 2) . AHR activation by its ligand 2,3,7,8-tetrachlorodibenzo-pdioxin (TCDD) induces functional Treg cells that suppress experimental autoimmune encephalomyelitis (EAE). On the other hand, AHR activation by 6-formylindolo [3,2-b] carbazole (FICZ) interferes with Treg-cell development, boosts Th17-cell differentiation and increases the severity of EAE in mice [51, 52] . These data imply that the reciprocal differentiation of Th17 and Treg cells is controlled by specific transcription factors, or at least in a ligand-dependent fashion. The differentiation of Th17 cells is also negatively regulated by other transcription factors. These transcription factors include T-box-containing protein expressed in T cells (T-bet) [60] , GATA-binding protein 3 (GATA3) [61] , E26 transformation specific-1 (Ets-1) [62] , STAT5 [63] , STAT1 [47] , suppressors of cytokine signalling 3 (SOCS3) [64, 65] , peroxisome proliferators-activated receptor g (PPARg) [66] and Foxp3 [39] .
In summary, these data have important implications for how the balance between Th17 and Treg cells is maintained in the presence of pro-and anti-inflammatory cytokines and the activation of positive and negative transcription factors. More importantly, the abilities of these transcription factors to regulate Treg-and Th17-cell differentiation make them specific targets for the therapeutic manipulation of autoimmune diseases.
Regulation of Th17-and Treg-cell differentiation by therapeutic agents Currently, there are several reported therapeutic agents that may be able to regulate the reciprocal differentiation of Th17 and Treg cells ( Table 2) . Inhibition of EAE through TCDD-induced AHR activation was associated with a significant increase in Treg-cell frequencies and decreased Th17-cell frequencies [51] . However, TCDD is very toxic in animal and human studies, and is far from clinical application in the treatment of autoimmune diseases.
The vitamin A metabolite all-trans-retinoic acid (RA) is capable of inhibiting the IL-6-driven induction of Th17 cells and promoting anti-inflammatory Treg-cell differentiation [34] . Recent study showed that RA enhances TGF-b signalling by increasing the expression and phosphorylation of Smad3. RA also inhibits the expression of IL-6Ra, IRF-4 and IL-23R, thus inhibiting Th17 development in vitro [67] . Additional studies confirmed that RA can relieve inflammatory diseases through regulation of the Th17 and Treg cell balance [68, 69] . These data indicate that a common metabolite can regulate the balance between pro-and anti-inflammatory immune responses. 51, 70] . This results in a concomitant decrease in Th17-cell differentiation and a subsequent immune balance between Th17 and Treg cells. Together, these data suggest that it may be possible to identify therapeutic agents that regulate the balance between Th17 and Treg cells for the treatment of SLE.
Conclusions
The potent pro-inflammatory activities of Th17 cells can explain a number of pathological features of SLE, such as the induction of vascular inflammation, recruitment of leucocytes, activation of B cells and autoantibody production [16, 20, 24] . Treg cells in SLE patients are deficient in number and in their ability to control the function of effector T cells. This results in a failure to maintain immunological homeostasis and attenuate autoimmune injuries [10, 11, 71] . Furthermore, there is evidence that Th17 and Treg cells arise in a reciprocal manner, depending on potentially pro-or anti-inflammatory cytokines and activation of specific transcription factors. Therefore, therapeutic agents that can regulate the immune balance between Treg (Yin) and Th17 (Yang) cells by modulating the pro-or anti-inflammatory cytokines and the specific transcription factors, may be promising choices for the treatment of SLE.
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